Uloga lipoprotein asocirana fosfolipaza A2 u predikciju i ocjena tezina koronarne arterske bolesti kod pacienata sa dijabetes mellitus tip 2

Lp-PLA2 i koronarna arteriska bolest

  • Irena Kostovska Institute of Medical and Experimental Biochemistry, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia https://orcid.org/0000-0003-0971-6710
  • Svetlana Cekovska Institute of Medical and Experimental Biochemistry, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
  • Katerina Tosheska Trajkovska Institute of Medical and Experimental Biochemistry, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
  • Danica Labudovic Institute of Medical and Experimental Biochemistry, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
  • Julijana Brezovska Kavrakova Institute of Medical and Experimental Biochemistry, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
  • Sonja Topuzovska Institute of Medical and Experimental Biochemistry, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
  • Hristina Ampova Institute of Medical and Experimental Biochemistry, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
  • Melda Emin Institute of Medical and Experimental Biochemistry, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
  • Elena Petrushevska Stanojevska Institute of Medical and Experimental Biochemistry, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
  • Natasa Nedeska Minova 8–th September City General Hospital, Department of Endocrinology, Diabetes and Metabolic Diseases, Skopje, Republic of North Macedonia
  • Ognen Kostovski University Clinic of Digestive Surgery, Clinical Center “Mother Theresa”, 1000, Skopje, North Macedonia
  • Marjan Boshev University Clinic of Cardiology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, North Macedonia
DOI: https://doi.org/10.5937/jomb0-57486

Sažetak


Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a specific biomarker associated with an increased risk of coronary artery disease (CAD) development. This study aims to determine the relationship between Lp-PLA2 activity and the risk of development and severity of CAD in patients with type 2 Diabetes mellitus (T2DM).

Methods: The cross-sectional study included 148 patients with T2DM, divided into two groups: patients with T2DM without confirmed CAD (n=56) and patients with T2DM and confirmed CAD (n=92), further divided into three subgroups based on the stage of CAD, and a control group of healthy individuals (n=44). Venous blood samples were collected from all participants to measure glucose, cholesterol, triglycerides, HDL, LDL, C-reactive protein, urea, and creatinine levels using standard photometric methods. Lp-PLA2 activity was measured using a chemiluminescent immunoassay method.

Results: Patients with T2DM and confirmed CAD had significantly higher Lp-PLA2 levels than those without confirmed CAD and healthy individuals. A significant difference in Lp-PLA2 levels was found between the group without CAD, the patients with CAD divided into subgroups according to disease stage, and the healthy control group. A positive correlation was observed between Lp-PLA2 and BMI, glycated hemoglobin, total cholesterol, and HDL cholesterol. The optimal cutoff value for Lp-PLA2 < 250 ng/ml yielded a diagnostic sensitivity of 95.65% and specificity of 88.64% for patients with T2DM and diagnosed CAD.

Conclusion: Lp-PLA2 can be used as a predictor for developing and assessing the severity of CAD in patients with T2DM.

Reference

Li D, Zhao L, Yu J, Zhang W, Du R, Liu X, et al. Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis. Clin Chim Acta 2017; 465: 22-29.

New WHO statistics highlight increases in blood pressure and diabetes, other noncommunicable risk factors. Cent Eur J Public Health 2012; 20: 134-149.

Chen Y, Wang S, Li J, Fu Y, Chen P, Liu X, et al. The relationships between biological novel biomarkers Lp-PLA2 and CTRP-3 and CVD in patients with type 2 diabetes mellitus. J Diabetes 2024; 16(7): e13574.

Lee DY. Emerging Circulating Biomarkers for Enhanced Cardiovascular Risk Prediction. J Lipid Atheroscler 2024; 13(3): 262-279.

Zhu HA. Lp-PLA2, a Novel Potential Biomarker Predicting Cardiovascular Disease in Type 2 Diabetes Mellitus. Med Clin Rev 2016; 2: 11.

Zhang H, Gao Y, Wu D, Zhang D. The relationship of lipoprotein-associated phospholipase A2 activity with the seriousness of coronary artery disease. BMC Cardiovasc Disord 2020; 20, 295.

De Stefano A, Mannucci L, Tamburi F, Cardillo C, Schinzari F, Rovella V, et al. Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases. Int J Immunopathol Pharmacol 2019; 33: 2058738419827154.

Zhang S, Wang J, Chen S, Zhang Y, He R, Wang X, et al. Serum levels of lipoprotein-associated phospholipase A2 are associated with coronary atherosclerotic plaque progression in diabetic and non-diabetic patients. BMC Cardiovasc Disord 2024; 24(1) :251.

Bargieł W, Cierpiszewska K, Maruszczak K, Pakuła A, Szwankowska D, Wrzesińska A, et al. Recognized and Potentially New Biomarkers-Their Role in Diagnosis and Prognosis of Cardiovascular Disease. Medicina 2021; 57(7): 701.

Baziar N, Nasli-Esfahani E, Djafarian K, Qorbani M, Hedayati M, Mishani MA, et al. The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. Oxid Med Cell Longev. 2020; 2020: 5850865.

Kurniawan LB, Rampo H, Soraya GV, Adnan E , Esa T, Widaningsih Y, et al. Effect of obesity, glucose control, lipid profiles, and blood pressure on Lp-PLA2 levels in type 2 Diabetes Mellitus patients. Obes Med 2021; 22: 100318

Naito R, Kasai T. Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives. World J Cardiol 2015; 7(3):119-24.

Nelson TL, Biggs ML, Kizer JR, Cushman M, Hokanson JE, Furberg CD, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study. J Clin Endocrinol Metab 2012; 97(5): 1695-701.

Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2021. Results. Institute for Health Metrics and Evaluation. 2024 (https://vizhub.healthdata.org/gbd-results/).

Garg S, Madhu SV, Suneja S. Lipoprotein associated phospholipase A2 activity & its correlation with oxidized LDL & glycaemic status in early stages of type-2 diabetes mellitus. Indian J Med Res 2015; 141(1): 107-14.

Chen YH, Li WC, Chen YC, Yeh WC, Yu W, Hung HY, et al. The correlation between lipoprotein associated phospholipase A2 and central overweight status. Int J Immunopathol Pharmacol. 2021; 35: 20587384211048562.

Sairam SG, Sola S, Barooah A, Javvaji SK, Jaipuria J, Venkateshan V, et al. The role of Lp-PLA2 and biochemistry parameters as potential biomarkers of coronary artery disease in Asian South-Indians: a case-control study. Cardiovasc Diagn Ther 2017; 7(6): 589-597.

Objavljeno
2025/04/29
Broj časopisa
Vol. 44 Br. 7 (2025): Journal of Medical Biochemistry
Rubrika
Original paper

Sva prava zadržana (c) 2025 Irena Kostovska, Svetlana Cekovska, Katerina Tosheska Trajkovska, Danica Labudovic, Julijana Brezovska Kavrakova, Sonja Topuzovska, Hristina Ampova, Melda Emin, Elena Petrushevska Stanojevska, Natasa Nedeska Minova, Ognen Kostovski, Marjan Boshev

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.